GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today the successful completion of the previously announced tender offer (the "Offer") to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) ("Syncona"). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled t

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) ("Syncona") has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones. The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022. The tender offer was previously scheduled to exp

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement of specified milestones. We urge you to tender your shares in the offer.In order to tender, please contact your bank or broker, or follow the instructions that you previously received by mail or email from

BTIG initiated coverage of Applied Genetic with a rating of Buy and set a new price target of $11.00

Stifel Nicolaus initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

Stifel initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

15-12G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

Leading Ophthalmologist and Experienced Industry Executive to Advance Development of Innovative Corneal Endothelial Cell Therapy Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer. Dr. Goldstein will lead the Company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothelial dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.c

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the appointment of James Robinson, President and Chief Executive Officer (CEO) of Urovant Sciences, to its Board of Directors. "We are honored to have Jim join our Board of Directors, where his exemplary track record of execution as an executive at leading biotech and pharma companies will b

With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC's preclinical pipeline GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer. "A gene

Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC's closing stock price on October 21, 2022 Total consideration of up to $1.07, including up to $0.73 per CVR, representing a premium of up to approximately 344% over AGTC's closing stock price on October 21, 2022 AGTC's Board has examined all alternative options for the future of AGTC and believes this transaction clearly delivers the best value for shareholders Given the state of equity and other funding markets, AGTC sees significant challenges in funding ongoing operations beyond 2022 Syncona and AGTC to host conference call on October 24, 2022 at 7:30 a.m. ET

– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study's Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host Conference Call to Review Data on May 17 at 8:00 a.m. ET – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited ret

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced financial results for the quarter ended December 31, 2021. "We enter 2022 with significant momentum from the recent buildout of our management team

SC 13G/A - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

SC 13D - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

SC 13G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)